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Abstract
Lysostaphin is a staphylolytic protein of growing interest from biotechnological and pharmaceutical industry due to its 
potential use in preventing and combating staphylococcal infections. Here, we describe an optimized method for production 
of lysostaphin in an inductionless system utilizing constitutive promoter from staphylococcal toxin–antitoxin system PemIK-
Sa1. We investigated the influence of ribosome-binding site sequence, Escherichia coli producer strain and growth media 
on yield and kinetics of recombinant protein production. Lysostaphin was purified in its native active form using one-step 
cation-exchange chromatography. The system provides a method for cost-efficient and scalable protein production, and can 
be applied to produce other biotechnologically significant proteins.
Keywords Lysostaphin · Protein expression · Ion exchange chromatography · Staphylococcus · Recombinant protein · 
Toxin–antitoxin system
Introduction
Many different expression systems have been developed to 
date, but the production of recombinant proteins in Escheri-
chia coli remains the most widely used [1]. E. coli offer 
high growth rate and inexpensive substrates which allow for 
scalable and cost-efficient production. Additionally, broad 
prevalence of the system results in availability of numerous 
host strains and variety of expression vectors.
Most expression systems rely on inducible promoters ena-
bling control over the onset of protein production. Biomass 
is usually first produced and only then the culture is switched 
to production. Apart from clear advantages, the inducible 
systems, including the most widely utilized lac promoter 
[2], its derivatives, tac/trc promoter [3, 4] and ara promoter 
[5], require expensive inducers, a considerable burden in 
large scale production. Other inducible promoters respond to 
temperature [6], pH [7] or depletion of particular substrates 
[8, 9], but provide less stringent control and have not been 
widely used.
Tightly controlled strong promoters have been conven-
tionally utilized [10], although often result in inactive, 
insoluble protein, deposited in inclusion bodies [11, 12]. 
Additionally, high level of mRNA can lead to ribosome 
destruction [13] and metabolic burden associated with 
overexpression [14] may lead to cell death. An alternative 
approach uses constitutive promoters. Continuous produc-
tion from weak promoters allows gradual accumulation and 
often more efficient folding. Another advantage is in cost 
reduction by eliminating the inducers.
Lysostaphin is a bacteriolytic metalloprotease originat-
ing from Staphylococcus simulans biovar staphylolyticus. It 
degrades the cell wall of multiple species of staphylococci 
by hydrolysis of pentaglycine crosslinks within peptidogly-
can [15, 16]. The gene encoding lysostaphin (end) is located 
on pACK1 plasmid together with epr gene which provides 
host resistance. The resistance is ensured by increased num-
ber of serine residues in the cross bridges [17, 18]. Native 
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lysostaphin is composed of mature polypeptide of 246 amino 
acid residues, propeptide of 211 residues and signal peptide 
of 36 residues [19]. The signal peptide is removed upon 
secretion and the propeptide is processed outside the cell 
by an extracellular cysteine protease [20, 21]. The mature 
lysostaphin is a protein of 27 kDa and isoelectric point of 
approximately 9.5 [22].
Lysostaphin had been shown effective in treatment of 
staphylococcal infections [23, 24] and reduction of staphy-
lococcal carriage [25, 26], but has not been translated to 
clinics. After a period of relative stagnation, medical lys-
ostaphin is being rediscovered against multidrug-resistant 
MRSA (Meticillin-resistant Staphylococcus aureus) and 
VRSA (Vancomycin-resistant Staphylococcus aureus) [27, 
28], as well as notoriously recalcitrant biofilms [29, 30]. Lat-
est concepts incorporate lysostaphin into medically relevant 
materials, which include coating of orthopedic implants with 
polymer matrix containing lysostaphin and manufacturing 
gels or wound-dressing materials for the treatment of topical 
or wound infections [31–35]. Lysostaphin-containing mate-
rials were proven useful in both preventing and eradicating 
S. aureus infections linked to orthopedic implants in murine 
model. Furthermore, a biopolymer impregnated with lys-
ostaphin had the antistaphylococcal activity comparable to 
commercially available antimicrobial wound dressings [36]. 
The growing interest in lysostaphin as an antistaphylococ-
cal agent calls for a cost-effective and scalable method of 
production.
Aside potential clinical use, lysostaphin is an indispensa-
ble tool in research and diagnostics. Lysostaphin treatment 
remains the most effective method for lysing staphylococcal 
cells. This is because other common methods including alka-
line lysis, sonication and homogenization are ineffective for 
staphylococci [37]. Lysostaphin is thus essential for extrac-
tion of nucleic acids and intracellular proteins. The enzyme 
is currently available from commercial sources, although 
relatively expensive. As a result, laboratories with sufficient 
experience may benefit from a non-complicated and reliable 
expression system to produce the enzyme on their own.
Several methods of lysostaphin expression and purifica-
tion have been described to date. The enzyme was purified 
from Staphylococcus simulans conditioned media [38–42], 
however, with poor yield. Additionally, such produced 
enzyme may contain contaminating allergens and pyro-
gens. Alternatively, production in heterologous hosts has 
been reported including E. coli [43–50], Bacillus subtilis 
and Lactobacillus casei [51], Pichia pastoris [52] and even 
in mammalian cells [53]. The most promising system in 
terms of efficient large scale production was developed in 
E. coli and based on an inducible promoter. Prior proposed 
systems required multi-step purification and often relied on 
immobilized metal ions chromatography, which is known 
to compromise lysostaphin activity due to leakage of metal 
ions, which are lysostaphin inhibitors [46]. No system based 
on a constitutive promoter and providing single-step purifi-
cation has been proposed to date.
Toxin–antitoxin (TA) systems are widely spread among 
bacteria and contribute to maintenance of mobile genetic 
elements, mediate phage infection defense, stress adaptation 
[54] and other functions. While investigating the staphylo-
coccal pemIK-Sa1 toxin–antitoxin system [55] we observed 
continuous expression of GFP (green fluorescent protein) 
under pemIK-Sa1 promoter increasing with culture density. 
This attractive characteristics prompted us to test the util-
ity of the promoter in circumventing the need of inducible 
expression for efficient recombinant protein production.
In this study, we provide an efficient expression system 
for recombinant lysostaphin in E. coli. The system utilizes 
a constitutive, non-inducible promoter from pemIK-Sa1 
toxin–antitoxin system. Furthermore, the system is con-
structed using an easily available pUC18 backbone suitable 
for cost-effective commercial production of recombinant 
proteins. Furthermore, we introduce a one-step ion exchange 
chromatography purification resulting in highly active and 
pure preparation. Altogether, our system allows rapid, effi-
cient, scalable and cost-effective production of recombinant 
lysostaphin, which may easily be adapted for use in pharma-
ceutical and biotechnological applications.
Materials and Methods
Bacterial Strains and Culture Conditions
E. coli Top10 and DH5α were used for cloning and plasmid 
propagation, respectively. Both above-mentioned strains and 
BL21(DE3) were used to test protein expression. The bacte-
ria were cultivated in Luria–Bertani Broth (LB, Sigma) or 
Tryptic Soy Broth (TSB, Sigma). The media were supple-
mented with 100 μg/ml ampicillin to assure plasmid main-
tenance. The cultures were cultivated at 37 °C with shaking.
Construction of Expression Vectors
The promoter sequence of pemIK-Sa1 toxin–antitoxin 
system was cloned into pTZ57R/T plasmid using InsTA-
clone™ PCR Cloning Kit (Thermo Scientific). The promoter 
sequence was amplified using pCH91 plasmid template [55] 
and RUN polymerase (A&A Biotechnology) with two differ-
ent primer pairs. promF and promR1 were used to introduce 
an E. coli-derived RBS while promF and promR2 introduced 
staphylococcal RBS (Table 1). Gel-purified PCR products 
were ligated into pTZ57R/T plasmid resulting in pTZ57R/
promEco and pTZ57R/promSau constructs.
GFP and the mature lysostaphin coding sequences were 
cloned into pUC18 vector. Additionally, lysostaphin with 
776 Molecular Biotechnology (2019) 61:774–782
1 3
C-terminal His-tag was prepared. The sequences were ampli-
fied with following pairs of primers: GFPSacI and GFPPstI 
for GFP, and lizoSacI_For and lizoPstI_Rev or lizoSacI_For 
and lizoHisPstI_Rev for lysostaphin. Plasmids pALCP2G 
[55] and pBADLys [46] encoding GFP and lysostaphin, 
respectively, were used as templates. The PCR products and 
pUC18 plasmid were digested with SacI and PstI (Thermo 
Scientific) and ligated with T4 DNA ligase (Thermo Sci-
entific). Resulting constructs were denoted as pUC18/GFP, 
pUC18/Lysostaphin and pUC18/Lysostaphin-His6.
Regulatory sequences were transferred from pTZ57R-
based plasmids prepared before into pUC18/GFP, pUC18/
Lysostaphin and pUC18/Lysostaphin-His6. All plas-
mids were digested with EcoRI and SacI and the regula-
tory sequences were ligated upstream the protein coding 
sequence. This resulted in a construct for expression of GFP 
and four constructs for expression of lysostaphin, namely 
pUC18/promEco/GFP, pUC18/promEco/Lysostaphin, 
pUC18/promEco/Lysostaphin-His6, pUC18/promSau/Lys-
ostaphin and pUC18/promSau/Lysostaphin-His6. Best con-
structs for recombinant lysostaphin production (pUC18/
promEco/Lysostaphin and pUC18/promSau/Lysostaphin) 
were deposited in Addgene (IDs 125765 and 125766, 
respectively).
Lysostaphin Activity Assay
Lysostaphin activity was determined by monitoring the 
decrease in the optical density (OD) at 600 nm of suspen-
sion of susceptible S. aureus cells. An overnight culture 
of S. aureus RN4220 was diluted to an optical density of 1 
in 0.1 M phosphate buffer, pH 7.5. The sample tested was 
diluted 10 times in L buffer (50 mM  NaH2PO4, 300 mM 
NaCl, pH 8.0) in a 96-well plate. In each case 100 μl of the 
tested sample dilution was mixed with 100 μl of S. aureus 
cell suspension. The OD was followed with a  micro-
plate reader (PowerWaveXSelekt, Bio-Tek Instruments) 
for 30 min. The activity was expressed in arbitrary units 
calculated as follows. The blank-corrected Δ  OD600nm 
t0 − t30 was set as a value of 100 and for each time point 
the respective Δ  OD600nm the proportional value from the 
range 100 to 0 was assigned. Activity is expressed as 50 
(corresponding to the half of initial  OD600nm value) divided 
by the time (in minutes) when  OD600nm reached the value.
GFP Reporter Assay for Determination of Promoter 
Activity
Overnight cultures of E. coli Top10, DH5α and 
BL21(DE3) cells transformed with pUC18/promEco/
GFP were diluted 1:100 in 20 ml of LB supplemented with 
100 μg/ml ampicillin and cultivated at 37 °C with shak-
ing. Samples of 0.5 ml were collected each hour. The cells 
were pelleted, resuspended in 0.5 ml of phosphate-buffered 
saline (pH 7.4) and sonicated (30 pulses, 500 ms, 80% 
amplitude) using UP50H ultrasonic processor (Hielscher). 
The fluorescence of the lysates was determined with Pow-
erWave microplate reader (Biotek) at 480 nm (excitation) 
and 510 nm (emission).
Optimization of Protein Production
To establish the best conditions for lysostaphin produc-
tion, the kinetics of the recombinant protein expression 
from pUC18/promEco/Lysostaphin and pUC18/promEco/
Lysostaphin-His6 plasmids was examined. Bacterial host 
strain, the growth medium and the time of cultivation were 
subject of optimization. Lysostaphin production was moni-
tored by determining the staphylolytic activity of tenfold 
diluted lysate as well as by SDS-PAGE of the whole lysate, 
and its soluble and insoluble fractions.
The overnight cultures were diluted 1:100 in 50 ml of 
tested medium supplemented with 100 μg/ml ampicillin. 
The bacteria were grown at 37 °C with shaking and first 
sample (2 ml) was taken 4 h after inoculation. Next sam-
ples were taken every hour for subsequent 7 h. The last 
sample was taken 24 h since the start of the culture. Sam-
ples were pelleted by centrifugation and the pellets were 
suspended in 200 μl of buffer L. 50 μl of every sample 
was set aside for total cell protein analysis. The remaining 
150 μl were sonicated (5 series of 30 pulses, 800 ms, 80% 
power) to obtain clear lysates. The samples were clarified 
by centrifugation (10 min, 4 °C, 15,000×g). The superna-
tant was used to assay the protein content of the soluble 
fraction while the pellet included the insoluble fraction. 
The pellets were resuspended in 100 μl of buffer L. All 
samples were analyzed by SDS-PAGE [56].
Table 1  Sequence of primers used in this study
Sequences recognized by restriction enzymes are underlined and RBS 
sequences are highlighted in bold
Primer Sequence (5′–3′)
lizoHisPstI_Rev CGC CTG CAG TCA ATG ATG ATG ATG ATG ATGC 
lizoPstI_Rev CGC CTG CAG TCA CTT TAT AGT TCC CCA AAG 
lizoSacI_For GAA GAG CTC AGC TGC AAC ACA TGA ACA TTC 
GFPSacI GGAG CTC AAA AGG AGA ACT TTT CAC TGG 
GFPPstI GCTG CAG TTA TTT GTA AAG CTC ATC CATGC 
promR1 GTT CTG CAG AGCTC ATCTG TAT ATC TCC 
TTTT GTT CAT CAT AAC AAA TG
promR2 GTT CTG CAG AGCTC ATAAA TAA TCA TCC 
TCCT TTT GTT CAT CAT AAC AAA TG
promF GAGAA TTC CAT TAA TTA ACA TAA ATG GG
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Production and Purification of Lysostaphin
Overnight culture of E. coli DH5α transformed with pUC18/
promEco/Lysostaphin was diluted 1:100 in 200 ml of TSB 
supplemented with 100 μg/ml ampicillin and cultured at 
37 °C with shaking for 16 h. The cells were pelleted, resus-
pended in 10 ml of buffer A (50 mM sodium phosphate, 
pH 7.5) and sonicated on ice (6 pulses of 30 s, 1 min inter-
vals, maximum power) with UD-11 ultrasonic disintegra-
tor (Techpan). The lysate was clarified by centrifugation 
(20 min, 4 °C, 15,000×g). The supernatant was applied 
(2 ml/min) onto 15 ml of cation-exchanger Source S30 resin 
(GE Healthcare Life Sciences) equilibrated with buffer A. 
The column was washed with 60 ml of buffer A. Elution was 
performed in linear gradient of buffer B (50 mM sodium 
phosphate, 1 M NaCl, pH 7.5) from 0 to 30% in a total vol-
ume of 150 ml. 2 ml fractions were collected. The frac-
tions containing lysostaphin were pooled and concentrated 
10 times using Amicon Ultra-15 Centrifugal Filter Units 
with MWCO of 3000 kDa (Merck). The preparation was 
dialyzed twice against buffer D (10 mM sodium acetate, pH 
4.5) at 4 °C. The purified protein was aliquoted, frozen in 
liquid nitrogen and lyophilized (Christ LDC-1, Alpha 1–4 
liophilizer). The protein concentration was determined by 
measurement of the absorbance at 280 nm (extinction coef-
ficient: 2.43/cm/mg ml).
Results
During functional investigation of staphylococcal PemIK-
Sa1 toxin–antitoxin system we noticed that the pemIK-Sa1 
promoter is transcriptionally active in E. coli, despite of the 
fact that E. coli are phylogenetically distant from S. aureus. 
E. coli transformants carrying a shuttle plasmid encoding 
pemIK-Sa1 driven GFP were green on agar plates. We took 
advantage of this observation to construct a vector for induc-
tionless expression of recombinant proteins in E. coli. As a 
proof of concept, we first prepared a pUC18-based plasmid 
encoding a widely utilized GFP reporter. Another pUC18 
based plasmids were prepared containing lysostaphin or lys-
ostaphin appended with His-tag at the C terminus to demon-
strate our idea using a protein of interest for biotechnology. 
PemIK-Sa1 promoter was engineered into both plasmids in 
two variants. Since the original pemIK-Sa1 TA promoter 
contains a non-canonical ribosome-binding site (AAGG 
GGG CTG ATA GTA ATG ), our plasmid variants contained 
RBS optimized for E. coli and S. aureus (AAG GAG ATA 
TCA GATG and AGG AGG ATG ATT ATTT ATG , respec-
tively) [57]. Having the genetic constructs at hand, we first 
assessed our concept by evaluating recombinant lysostaphin 
production in E. coli, in a simple end-point assay. Cells were 
collected from overnight cultures, lysed by sonication and 
lysostaphin activity in crude lysates was tested by monitor-
ing a decrease in optical density of S. aureus cell suspension. 
All tested promoter and lysostaphin variants demonstrated 
significant staphylolytic activity. No differences in activity 
(around 8.5 A.U.) were observed regardless of RBS variant 
and/or the presence of C-terminal His-tag (Fig. 1).
In the next step, the effect of host strain on the efficiency 
of recombinant protein production and the production kinet-
ics were evaluated. Here, we used the GFP-encoding plas-
mid with pemIK-Sa1 promoter, which allowed us to track the 
transgene expression by quantifying the cell fluorescence. 
Moreover, since GFP is fluorescent only in its native con-
formation [58] we monitored only accumulation of properly 
folded protein rather than its accumulation in inclusion bod-
ies. Three E. coli strains were tested: BL21(DE3), DH5α 
and TOP10. The first strain is routinely used for produc-
tion of recombinant proteins since it lacks Lon and OmpT 
protease encoding genes ensuring little or no recombinant 
protein degradation. The fact that the strain is additionally 
lysogenic for DE3 phage which allows T7 promoter-driven 
expression [59] was of no significance to this study. The 
two latter strains are generally used for DNA manipula-
tions, but not in protein expression. This is because both 
are DNA recombinase deficient  (recA−), which substantially 
reduces the risk of unspecific plasmid recombination, but 
not protease deficient. Recombinase deficiency is however 
of special interest when expressing toxic proteins in long-
lasting biotechnological processes, and for that reason we 
included those strain in evaluation. Through the experiment, 
the optical density of tested E. coli cultures was monitored 
and samples were taken at different time points to evaluate 
Fig. 1  Recombinant lysostaphin expression in E.  coli. Staphylolytic 
activity (shown as decrease in optical density of susceptible S. aureus 
suspension) of lysates prepared form E. coli DH5α transformed with 
the plasmids prepared in this study and encoding lysostaphin under 
the control of the pemIK-Sa1 promoter
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GFP fluorescence accumulation (Fig. 2). GFP production/
fluorescence accumulation mirrored the growth curves of 
tested cultures, regardless of the strain. Continuous expres-
sion during the logarithmic phase of growth was observed 
which reached a plateau as the culture entered the stationary 
phase—no further protein accumulation was noted. Interest-
ingly, the production yield differed substantially between 
tested strains. Top10 produced considerably less GFP (fluo-
rescence) compared to two other strains. The fluorescence 
(GFP) level obtained in DH5α and BL21(DE3) was compa-
rable and roughly twice that observed in Top10. However, 
BL21(DE3) reached higher OD600 nm and thus the fluores-
cence level (GFP production) per biomass unit was slightly 
lower compared to DH5α. As such, the latter strain was used 
for further optimization of lysostaphin production.
Composition of the growth medium is an important fac-
tor affecting the production yield of recombinant proteins 
[60]. Additionally, fusion tags may influence the expression 
efficiency, solubility and stability of the recombinant protein 
[61]. To optimize lysostaphin expression, we assessed the 
influence of the above factors on obtained yields. To this 
end, native and His-tagged lysostaphin were expressed in 
LB and rich TSB medium while monitoring the growth rate 
and transgene activity. Kinetics of lysostaphin production 
in LB was indifferent to the presence of C-terminal His-tag. 
The staphylolytic activity of lysates from both native and 
His-tagged lysostaphin expressing E. coli was roughly com-
parable at all time points tested (Table 2; Fig. 3). It increased 
gradually during the exponential growth phase indicating 
accumulation of the recombinant protein (Fig. 3). However, 
prolonged cultivation (24 h) resulted in decreased activity 
(Table 2; Fig. 3), likely because of secondary degradation. 
Both variants were produced only in the soluble form—no 
bands corresponding to the respective proteins were detected 
in insoluble fraction during SDS-PAGE, even at prolonged 
incubation times (Fig. 3). The kinetics of recombinant lys-
ostaphin production was largely different in TSB compared 
to LB. Time-dependent increase in staphylolytic activity of 
native lysostaphin was observed through the entire culture 
(up to 24 h), while the activity of His-tagged protein dropped 
substantially after prolonged cultivation (24 h) compared to 
that accumulated at 11 h. SDS-PAGE revealed decrease of 
the corresponding protein band in soluble fraction which 
suggests proteolytic degradation rather than conversion to 
inclusion bodies (Fig. 3). Interestingly, the activity of lysates 
containing lysostaphin of native sequence was substantially 
higher when the bacteria were grown in TSB compared to 
LB (Table 2). Therefore, we chose E. coli DH5α transformed 
with pUC18/promEco/Lysostaphin cultivated in TSB up to 
stationary phase (16 h post inoculation) for preparative pro-
duction of recombinant lysostaphin. 
Protein purification in the absence of affinity tags is gen-
erally relatively challenging unless the protein of interest has 
unique features enabling application of dedicated isolation 
method. To recover the recombinant lysostaphin, we took 
advantage of its relatively high-isoelectric point (pI 9.5), 
which allowed advantageous fractionation using strong 
cation exchanger. Clarified E. coli lysate was passed over 
Source S30 at pH 7.5 retaining lysostaphin. Rather strik-
ingly, this afforded a very efficient, single-step purification 
as the vast majority of endogenous proteins did not bind at 
these conditions. Virtually pure lysostaphin (> 95% purity 
in SDS-PAGE) was recovered with low-sodium chloride in 
the loading buffer (Fig. 4). Lysostaphin-containing fractions 
were pooled, concentrated, dialyzed against storage buffer, 
and lyophilized. The procedure resulted in 20–25 mg of lys-
ostaphin from 1 l of bacterial culture.
Discussion
In this study, we took advantage of the features of the pro-
moter derived from staphylococcal PemIK-Sa1 toxin–anti-
toxin system to design an induction-free platform for effi-
cient production of recombinant proteins. The utility of the 
Fig. 2  Evaluation of recombinant protein expression in different E. 
coli strains. GFP was cloned under control of pemIK-Sa1 TA pro-
moter and expression was evaluated in indicated E. coli strains. Opti-
cal density (OD600 nm) and GFP fluorescence are shown
Table 2  Staphylolytic activity of lysates from E.  coli DH5α trans-
formed with the plasmids encoding different variants of lysostaphin 




Time post inoculation (h) 11 24 11 24
LB medium (A.U.) 14.8 8.0 18.1 11.0
TSB medium (A.U.) 17.7 33.8 13.6 4.9
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platform was exemplified by expression of lysostaphin, an 
important antistaphylococcal agent attracting a growing 
interest of pharmaceutical and biotechnology industry [34, 
35, 62].
RBS sequences allow to fine-tune protein expression. 
Often the expression of genes clustered in operons is varied 
by differing the RBS sequences. In TA systems for example, 
the antitoxin is usually produced in higher amounts than the 
downstream-encoded toxin [63]. To bypass the expected low 
expression from non-canonical RBS, we optimized its origi-
nal sequence to that characteristic for E. coli and S. aureus. 
Strikingly, we did not observe any difference in activity or 
kinetics of lysostaphin production from these two distinct 
RBS sequences when evaluated in E. coli. This indicates that 
in our particular example, the limiting feature is the strength 
of the promoter, but not the RBS.
The kinetics of protein production driven by the tested 
pemIK-Sa1 constitutive promoter matched that described 
previously for other staphylococcal toxin–antitoxin systems 
belonging to the same class, namely mazEF and savRS [64, 
65]. The promoter was active during logarithmic growth 
phase. In the late stationary phase, degradation of recom-
binant protein was observed and for this reason the optimal 
time of harvest coincided with the peak of optical density at 
the early stationary phase.
Production of recombinant proteins is among biotechno-
logical processes resulting in high value products. Factors 
influencing profitability include efficiency and the cost of an 
Fig. 3  Comparison of production efficacy of different variants of 
recombinant lysostaphin in different media. Native sequence and 
His-tagged lysostaphin were expressed in E. coli cultured in LB or 
TSB. Staphylolytic activity and protein levels were monitored. Sam-
ples were taken every hour till the 11th hour (exponential growth) 
and at 24th hour (stationary phase)—selected time points are shown 
for clarity. Panels beneath the graphs show SDS-PAGE of the whole 
lysate (L) and the soluble (S) and the insoluble (IS) fractions. Bands 
corresponding to lysostaphin are marked with arrowheads
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expression platform and downstream processing—such as 
purification [66]. We provided the procedure based on gen-
erally accessible pUC18-based vectors and E. coli strains to 
produce mature lysostaphin in one-step purification. pUC18 
is a high copy number plasmid which compensates the use 
of a relatively weak promoter.
A method of lysostaphin purification has been previ-
ously described based on immobilized metal ion affin-
ity chromatography [46–48]. Histidine tagging has not 
affected the activity, but our results show that it may sig-
nificantly affect protein stability. What is more, lysostaphin 
is a  Zn2+-dependent metalloprotease and trace  Ni2+ or  Co2+ 
ions released from the resin during purification result in 
significant decrease in enzymatic activity by substituting 
the catalytic  Zn2+ ion [46].  Zn2+ affinity chromatography 
was proposed as an alternative [67, 68], but a two-step pro-
cedure including additional ion-exchange chromatography 
was necessary to obtain relevant purity. Not only the two-
step procedure, but even the relatively high concentrations 
of imidazole necessary for elution substantially increase 
the costs of high-scale industrial purification. Moreover, it 
was recently reported that excess exogenous  Zn2+ inhibits 
lysostaphin [69]. Even the more, some applications require 
the recombinant protein in its native form (i.e. without 
expression and purification tags) while precise tag removal 
is often impossible or requires additional reagents (i.e. pro-
teases) and steps (i.e. tag removal, protease removal) which 
substantially increase the production costs and contribute 
additional impurities to the final preparations [46]. Here, 
we described a single-step, cation-exchange chromatogra-
phy-based procedure yielding pure preparations of native 
sequence lysostaphin. Our approach overcomes the limita-
tions of prior techniques proposed for lysostaphin purifi-
cation. In the optimized conditions of pH 7.5, only a few 
proteins other than lysostaphin bind to the resin and none 
of those endogenous E. coli proteins co-eluted with the pro-
tein of interest. This phenomenon is explained by a bimodal 
distribution of isoelectric points (pI) in bacterial proteome 
[70]. Nearly two-thirds of E. coli proteins have theoretical pI 
below 7.5 and thus exhibit negative or neutral charge at the 
pH used for purification excluding their binding to a cation 
exchanger. The majority of remaining E. coli proteins with 
higher theoretical isoelectric points are classified among 
membrane proteins, and as such are absent in the clarified 
lysate. Such distribution of isoelectric points among E. coli 
proteins opens the possibility to apply cation exchange in 
one-step purification of not only lysostaphin, but also other 
recombinant proteins characterized by high values of pI, 
using procedures described in this study.
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